Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 14:35:54 2024-05-20 EDT			5-day change	1st Jan Change
33.95 ^USD	-1.14%		+1.13%	+52.31%

05-16	Transcript : Agios Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM
05-02	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	MT

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

September 07, 2022 at 07:03 am

Agios Pharmaceuticals, Inc. announced that Jonathan Biller notified the Company of his intention to resign as chief financial officer on September 6, 2022, head of corporate affairs and principal financial officer of the Company, effective September 16, 2022, in order to pursue other opportunities.

Latest news about Agios Pharmaceuticals, Inc.

Transcript : Agios Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM	05-16
Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	05-02	MT
Transcript : Agios Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q1 Revenue $8.2M	05-02	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating	02-16	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises	02-15	MT
Transcript : Agios Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024	02-15
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
Transcript : Agios Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM	01-10
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing	01-09	MT
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	01-08	CI
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints	01-03	MT
Agios' blood disorder drug meets goals of late-stage study	01-03	RE
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	01-03	CI
Transcript : Agios Pharmaceuticals, Inc. - Special Call	01-03
Transcript : Agios Pharmaceuticals, Inc. - Special Call	12-11
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition	12-09	CI
Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes	11-20	CI
Goldman Sachs Adjusts Price Target on Agios Pharmaceuticals to $28 From $32, Maintains Neutral Rating	11-03	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Transcript : Agios Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023	11-02
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q3 Revenue $7.4M, vs. Street Est of $7.5M	11-02	MT
Transcript : Agios Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 07:30 AM	23-09-12

Chart Agios Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.

Sector

Biotechnology & Medical Research

Calendar

2024-06-14 - European Hematology Association Meeting - Abstract No. P2306

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Agios Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

34.34 USD

Average target price

41.67 USD

Spread / Average Target

+21.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AGIOS PHARMACEUTICALS, INC.	+52.31%	1.95B
VERTEX PHARMACEUTICALS INCORPORATED	+9.82%	115B
REGENERON PHARMACEUTICALS, INC.	+11.88%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.67%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.90%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.29%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.72%	12.42B

Bio Therapeutic Drugs